INTRODUCTION
Marfan syndrome is an autosomal dominant heritable disorder of the connective tissue involving the skeletal, ocular, and cardiovascular systems. Cardiovascular complications such as aortic rupture and mitral valve dysfunction affect the life expectancy of patients with this disorder [1] . While aortic disease is known to be responsible for most premature and sudden mortalities in adults with Marfan syndrome, mitral valve dysfunction is the most common cause of morbidity and mortality in infantile-onset Marfan syndrome [2] .
However, the choice between replacement and repair remains controversial, especially in infants and young children, because of the underlying degenerative process, their smaller heart size, and the necessity of anticoagulation therapy. We report our experience in the surgical management of mitral regurgitation in younger Marfan syndrome patients, in order to contribute to the ongoing search for the optimal surgical management of such patients. 
RESULTS
Of the six patients, three were boys and three were girls (Table 1) . They were diagnosed with Marfan syndrome at a median of 11.5 months old (range, 3 to 60 months) based on family history, genetic testing, and characteristic skeletal, ocular, and cardiovascular manifestations. Their median aortic root Z-value was 8.5 (range, 4.2 to 9.8).
The median age at the time of the operation was 47 months (range, 3 to 140 months) ( Table 2 ). The median in- Late mortality.
six patients showed symptoms of congestive heart failure, and four of them required intravenous inotropic support in the intensive care unit. Preoperative echocardiography revealed that all of the patients had mitral valve prolapse of both leaflets, leading to mitral regurgitation over nearly the entire area of the valve orifice. Their median mitral valve annulus Z-score was 6.5 (range, 3.0 to 7.9).
Mitral valve repair was done in two patients, and four patients underwent mitral valve replacement with mechanical prostheses (Table 3) The prognosis of infantile-onset Marfan syndrome is poor due to its association with severe cardiovascular manifestations.
Geva et al. [7] reported nine infants with infantile-onset (Fig. 1) . The different prognosis of these patients suggests that mitral valve repair is not necessarily durable in infantile-onset Marfan syndrome patients, especially in those who present with severe mitral regurgitation early in life.
Therefore, valve replacement is preferable to valve repair for this group of patients.
Valve replacement in infants is associated with significant mortality and morbidity, including complete heart block, thrombosis, and stroke [10] . However, the long-term mortality is quite favorable despite the need of reoperation for second valve replacements and long-term anticoagulation therapy.
Mitral valve replacement in infants or young children usually involves two considerations that optimize the long-term results. First, because of the substantial life expectancy of the patient, a mechanical prosthesis is preferable to tissue prosthesis. The second consideration relates to the optimal valve size. It is preferable to put in larger prosthetic valves in order to avoid the potential development of valve-patient mismatch resulting in reoperation as the child grows. Caldarone et al. [11] suggested that an increased valve size/body weight ratio is a predictor of increased early mortality associated with initial mitral valve replacement. While the one-year survival associated with a size/weight ratio of two is 91%
(corresponding to a 16 mm prosthesis in an 8 kg infant), it drops significantly to 61% when the size/weight ratio is four.
However, a large portion of these patients (74/139, 53.2%) had either complete atrioventricular canal defect or Shone's syndrome, which are associated with anatomic relationships that may account for higher mortality. In Marfan syndrome patients, the substantially dilated mitral annulus is usually large enough to fit in prosthetic valves with a large diameter without affecting the geometry of the heart. In our experience, patient 6 was the youngest and smallest, at nine months old and 7.6 kg at the time of operation. The patient's mitral annulus size was 35 mm and we had no problem placing a 23 mm prosthetic valve. Nevertheless, one has to be aware of the possibility of oversizing the mitral valve prosthesis.
In conclusion, mitral valve repair may not be feasible or durable in Marfan syndrome patients who require surgical management of mitral valve regurgitation during infancy or childhood. Although valve replacement in infants involves certain risks, our results suggest that mitral valve replacement with a mechanical prosthesis can be a good option for these patients. In addition, frequent follow-up is vital for determining the optimal timing of surgical management, in light of the rapid progressive nature of infantile-onset Marfan syndrome.
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